About Protalix BioTherapeutics
Protalix BioTherapeutics is a company based in Karmiel (Israel) founded in 1993. The company has 213 employees as of December 31, 2024. Protalix BioTherapeutics offers products and services including Elfabrio®, Elelyso®, and ProCellEx®. Protalix BioTherapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Karmiel, Israel
- Employees 213 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Protalix Biotherapeutics, Inc. (De)
-
Annual Revenue
$53.4 M (USD)-18.47as on Dec 31, 2024
-
Net Profit
$2.93 M (USD)-64.73as on Dec 31, 2024
-
EBITDA
$5.22 M (USD)-55.19as on Dec 31, 2024
-
Latest Funding Round
$43.7 M (USD), Post-IPO
Mar 12, 2020
-
Investors
UBS
& 11 more
-
Employee Count
213
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Protalix BioTherapeutics
Protalix BioTherapeutics is a publicly listed company on the AMEX with ticker symbol PLX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Protalix BioTherapeutics
Protalix BioTherapeutics offers a comprehensive portfolio of products and services, including Elfabrio®, Elelyso®, and ProCellEx®.
Treats Fabry disease through recombinant protein administration.
Addresses Gaucher disease with therapeutic protein solutions.
Enables plant-based production of recombinant therapeutic proteins.
People of Protalix BioTherapeutics
Unlock access to complete
Leadership Team
7 people
Software Development Team
5 people
Scientific Team
3 people
Finance and Accounting
2 people
Operations Team
2 people
Human Resources and Administration
2 people
Senior Team
2 people
Chairman Team
1 people
Unlock access to complete
Funding Insights of Protalix BioTherapeutics
Investors in Protalix BioTherapeutics
Protalix BioTherapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include UBS, Pfizer and Mor Investment House.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-short strategy hedge fund and venture capital firm investing in tech companies
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investments are directed toward Israeli technology startups by Docor.
|
Locked | Locked | Locked |
Investor details for Protalix BioTherapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Protalix BioTherapeutics
Investment portfolio details for Protalix BioTherapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Protalix BioTherapeutics
Detailed financials for Protalix BioTherapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Protalix Biotherapeutics Comparisons
Peer comparison for Protalix BioTherapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Protalix BioTherapeutics
Protalix BioTherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Protalix BioTherapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Protalix Biotherapeutics
Complete news archive for Protalix BioTherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Protalix BioTherapeutics
Protalix BioTherapeutics was founded in 1993 and raised its 1st funding round 11 years after it was founded.
Protalix BioTherapeutics is headquartered in Karmiel, Israel. It is registered at Karmiel, Northern District, Israel.
As of Dec 31, 2024, the latest employee count at Protalix BioTherapeutics is 213.
Annual revenue of Protalix BioTherapeutics is $53.4M as on Dec 31, 2024.
Protalix BioTherapeutics was founded in 1993 in Karmiel, Israel, and operates in the biotechnology sector. Recombinant proteins are developed and commercialized using the ProCellEx plant cell expression system. A pipeline of novel and biosimilar proteins is pursued, with ELELYSO marketed as a glucocerebrosidase enzyme for Type 1 Gaucher disease. Additional recombinant proteins are under development for Fabry disease, immune and inflammatory conditions, and cystic fibrosis.
Protalix BioTherapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Protalix BioTherapeutics offers Elfabrio®, Elelyso®, and ProCellEx®.
Yes, Protalix BioTherapeutics is publicly traded on AMEX under the ticker symbol PLX.
Protalix BioTherapeutics has 12 investors. Key investors include UBS, Pfizer, Mor Investment House, European Union, and Alrov.
The ticker symbol of Protalix BioTherapeutics is PLX on AMEX.